Ítem
Acceso Abierto

New molecular approches using AR, FOXA1 and HER2 for outcome classification of estrogen Receptor-Positive (ER+) breast cancers”

Mostrar el registro sencillo de la publicación
dc.contributor.advisorSapino, Anna
dc.contributor.advisorRamírez Clavijo, Sandra Rocío
dc.creatorRangel Jiménez, Nelson Enrique
dc.creator.degreeDoctor en Ciencias Biomédicasspa
dc.creator.degreetypeFull timespa
dc.date.accessioned2019-01-28T12:46:33Z
dc.date.available2019-01-28T12:46:33Z
dc.date.created2018-06-06
dc.date.issued2018
dc.description.abstractHere, we studied new prognostic and predictive easy access strategies in breast cancer (molecular markers), for better classify ER+ breast cancer disease, which might provide additional information and be complementary to the clasical clinical-pathological prediction models.spa
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.48713/10336_18932
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/18932
dc.language.isospa
dc.publisherUniversidad del Rosariospa
dc.publisher.departmentFacultad de Ciencias Naturales y Matemáticasspa
dc.publisher.programDoctorado en Ciencias Biomédicasspa
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombiaspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.source.bibliographicCitationFerlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.spa
dc.source.bibliographicCitationCheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736-50.spa
dc.source.bibliographicCitationDai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5(10):2929-43.spa
dc.source.bibliographicCitationNCI NCI-. SEER Cancer Stat Facts: Female Breast Cancer.: NCI; [Available from: http://seer.cancer.gov/statfacts/html/breast.html.spa
dc.source.bibliographicCitationEarly Breast Cancer Trialists' Collaborative Group, Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-84.spa
dc.source.bibliographicCitationRondon-Lagos M, Rangel N, Di Cantogno LV, Annaratone L, Castellano I, Russo R, et al. Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes. Endocr Relat Cancer. 2016;23(8):635-50.spa
dc.source.bibliographicCitationRondon-Lagos M, Villegas VE, Rangel N, Sanchez MC, Zaphiropoulos PG. Tamoxifen Resistance: Emerging Molecular Targets. Int J Mol Sci. 2016;17(8).spa
dc.source.bibliographicCitationVici P, Pizzuti L, Natoli C, Gamucci T, Di Lauro L, Barba M, et al. Triple positive breast cancer: a distinct subtype? Cancer Treat Rev. 2015;41(2):69-76.spa
dc.source.bibliographicCitationPerou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.spa
dc.source.bibliographicCitationSimpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol. 2005;205(2):248-54.spa
dc.source.bibliographicCitationHu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.spa
dc.source.bibliographicCitationEin-Dor L, Kela I, Getz G, Givol D, Domany E. Outcome signature genes in breast cancer: is there a unique set? Bioinformatics. 2005;21(2):171-8.spa
dc.source.bibliographicCitationWard S, Scope A, Rafia R, Pandor A, Harnan S, Evans P, et al. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2013;17(44):1-302.spa
dc.source.bibliographicCitationFitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124(7):966-78.spa
dc.source.bibliographicCitationSestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, et al. Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst. 2013;105(19):1504-11.spa
dc.source.bibliographicCitationGoldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-47.spa
dc.source.bibliographicCitationYasui Y, Potter JD. The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control. 1999;10(5):431-7.spa
dc.source.bibliographicCitationRoss JS, Symmans WF, Pusztai L, Hortobagyi GN. Breast cancer biomarkers. Adv Clin Chem. 2005;40:99-125.spa
dc.source.bibliographicCitationRusso J, Fernandez SV, Russo PA, Fernbaugh R, Sheriff FS, Lareef HM, et al. 17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells. FASEB J. 2006;20(10):1622-34.spa
dc.source.bibliographicCitationTai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146(3):264-75.spa
dc.source.bibliographicCitationSapino A, Goia M, Recupero D, Marchio C. Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues. Front Oncol. 2013;3:129.spa
dc.source.bibliographicCitationRoss JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999;112(1 Suppl 1):S53-67.spa
dc.source.bibliographicCitationWolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013.spa
dc.source.bibliographicCitationBallard M, Jalikis F, Krings G, Schmidt RA, Chen YY, Rendi MH, et al. 'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study. Mod Pathol. 2017;30(2):227-35.spa
dc.source.bibliographicCitationFan YS, Casas CE, Peng J, Watkins M, Fan L, Chapman J, et al. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline. Breast Cancer Res Treat. 2016;155(3):457-62.spa
dc.source.bibliographicCitationMargolis RN, Evans RM, O'Malley BW, Consortium NA. The Nuclear Receptor Signaling Atlas: development of a functional atlas of nuclear receptors. Mol Endocrinol. 2005;19(10):2433-6.spa
dc.source.bibliographicCitationClaessens F, Verrijdt G, Schoenmakers E, Haelens A, Peeters B, Verhoeven G, et al. Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. J Steroid Biochem Mol Biol. 2001;76(1-5):23-30.spa
dc.source.bibliographicCitationCuenca-Lopez MD, Montero JC, Morales JC, Prat A, Pandiella A, Ocana A. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer. 2014;14:302.spa
dc.source.bibliographicCitationAleskandarany MA, Abduljabbar R, Ashankyty I, Elmouna A, Jerjees D, Ali S, et al. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. Breast Cancer Res Treat. 2016;159(2):215-27.spa
dc.source.bibliographicCitationBozovic-Spasojevic I, Zardavas D, Brohee S, Ameye L, Fumagalli D, Ades F, et al. The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data. Clin Cancer Res. 2016.spa
dc.source.bibliographicCitationAndo S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML, et al. Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol. 2002;193(1-2):121-8.spa
dc.source.bibliographicCitationBirrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol. 1995;52(5):459-67.spa
dc.source.bibliographicCitationLin HY, Sun M, Lin C, Tang HY, London D, Shih A, et al. Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells. J Steroid Biochem Mol Biol. 2009;113(3-5):182-8.spa
dc.source.bibliographicCitationHilborn E, Gacic J, Fornander T, Nordenskjold B, Stal O, Jansson A. Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-alpha-negative breast cancer. Br J Cancer. 2016;114(3):248-55.spa
dc.source.bibliographicCitationQu Q, Mao Y, Fei XC, Shen KW. The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS One. 2013;8(12):e82650.spa
dc.source.bibliographicCitationAugello MA, Hickey TE, Knudsen KE. FOXA1: master of steroid receptor function in cancer. EMBO J. 2011;30(19):3885-94.spa
dc.source.bibliographicCitationHe K, Zeng H, Xu X, Li A, Cai Q, Long X. Clinicopathological significance of forkhead box protein A1 in breast cancer: A meta-analysis. Exp Ther Med. 2016;11(6):2525-30.spa
dc.source.bibliographicCitationGuiu S, Charon-Barra C, Vernerey D, Fumoleau P, Campone M, Spielmann M, et al. Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial. Future Oncol. 2015;11(16):2283-97.spa
dc.source.bibliographicCitationHu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011;17(7):1867-74.spa
dc.source.bibliographicCitationPark S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010;21(3):488-92.spa
dc.source.bibliographicCitationYu Q, Niu Y, Liu N, Zhang JZ, Liu TJ, Zhang RJ, et al. Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol. 2011;22(6):1288-94.spa
dc.source.bibliographicCitationCastellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat. 2010;124(3):607-17.spa
dc.source.bibliographicCitationNiemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010;23(2):205-12.spa
dc.source.bibliographicCitationAsano Y, Kashiwagi S, Goto W, Tanaka S, Morisaki T, Takashima T, et al. Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer. Cancers (Basel). 2017;9(1).spa
dc.source.bibliographicCitationJiang HS, Kuang XY, Sun WL, Xu Y, Zheng YZ, Liu YR, et al. Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status. Oncotarget. 2016;7(27):41285-93.spa
dc.source.bibliographicCitationLuo X, Shi YX, Li ZM, Jiang WQ. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer. 2010;29(6):585-90.spa
dc.source.bibliographicCitationPark S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol. 2011;22(8):1755-62.spa
dc.source.bibliographicCitationPistelli M, Caramanti M, Biscotti T, Santinelli A, Pagliacci A, De Lisa M, et al. Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. Cancers (Basel). 2014;6(3):1351-62.spa
dc.source.bibliographicCitationVera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(1):djt319.spa
dc.source.bibliographicCitationPeters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 2009;69(15):6131-40.spa
dc.source.bibliographicCitationCops EJ, Bianco-Miotto T, Moore NL, Clarke CL, Birrell SN, Butler LM, et al. Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. J Steroid Biochem Mol Biol. 2008;110(3-5):236-43.spa
dc.source.bibliographicCitationGreeve MA, Allan RK, Harvey JM, Bentel JM. Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21(Cip1/Waf1). J Mol Endocrinol. 2004;32(3):793-810.spa
dc.source.bibliographicCitationMacedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res. 2006;66(15):7775-82.spa
dc.source.bibliographicCitationNeed EF, Selth LA, Harris TJ, Birrell SN, Tilley WD, Buchanan G. Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor alpha in luminal breast cancer cells. Mol Endocrinol. 2012;26(11):1941-52.spa
dc.source.bibliographicCitationBuchanan G, Birrell SN, Peters AA, Bianco-Miotto T, Ramsay K, Cops EJ, et al. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res. 2005;65(18):8487-96.spa
dc.source.bibliographicCitationCochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014;16(1):R7.spa
dc.source.bibliographicCitationCoates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533-46.spa
dc.source.bibliographicCitationHammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-95spa
dc.source.bibliographicCitationSapino A, Marchio C, Senetta R, Castellano I, Macri L, Cassoni P, et al. Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch. 2006;449(3):288-96.spa
dc.source.bibliographicCitationMarchio C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol. 2009;219(1):16-24.spa
dc.source.bibliographicCitationBustreo S, Osella-Abate S, Cassoni P, Donadio M, Airoldi M, Pedani F, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat. 2016;157(2):363-71.spa
dc.source.bibliographicCitationDowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31(22):2783-90spa
dc.source.bibliographicCitationParker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-7.spa
dc.source.bibliographicCitationCastellano I, Chiusa L, Vandone AM, Beatrice S, Goia M, Donadio M, et al. A simple and reproducible prognostic index in luminal ER-positive breast cancers. Ann Oncol. 2013;24(9):2292-7.spa
dc.source.bibliographicCitationKim Y, Jae E, Yoon M. Influence of Androgen Receptor Expression on the Survival Outcomes in Breast Cancer: A Meta-Analysis. J Breast Cancer. 2015;18(2):134-42.spa
dc.source.bibliographicCitationGrogg A, Trippel M, Pfaltz K, Ladrach C, Droeser RA, Cihoric N, et al. Androgen receptor status is highly conserved during tumor progression of breast cancer. BMC Cancer. 2015;15:872.spa
dc.source.bibliographicCitationCimino-Mathews A, Hicks JL, Illei PB, Halushka MK, Fetting JH, De Marzo AM, et al. Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. Hum Pathol. 2012;43(7):1003-11.spa
dc.source.bibliographicCitationGonzalez LO, Corte MD, Vazquez J, Junquera S, Sanchez R, Alvarez AC, et al. Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer. 2008;8:149.spa
dc.source.bibliographicCitationFeng J, Li L, Zhang N, Liu J, Zhang L, Gao H, et al. Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms. Oncogene. 2016.spa
dc.source.bibliographicCitationPanet-Raymond V, Gottlieb B, Beitel LK, Pinsky L, Trifiro MA. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol. 2000;167(1-2):139-50.spa
dc.source.bibliographicCitationTakagi K, Miki Y, Nagasaki S, Hirakawa H, Onodera Y, Akahira J, et al. Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. Endocr Relat Cancer. 2010;17(2):415-30.spa
dc.source.bibliographicCitationCiupek A, Rechoum Y, Gu G, Gelsomino L, Beyer AR, Brusco L, et al. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERalpha-positive breast cancer. Breast Cancer Res Treat. 2015;154(2):225-37.spa
dc.source.bibliographicCitationDe Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, et al. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010;121(1):1-11.spa
dc.source.bibliographicCitationFujii R, Hanamura T, Suzuki T, Gohno T, Shibahara Y, Niwa T, et al. Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. J Steroid Biochem Mol Biol. 2014;144 Pt B:513-22.spa
dc.source.bibliographicCitationRechoum Y, Rovito D, Iacopetta D, Barone I, Ando S, Weigel NL, et al. AR collaborates with ERalpha in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2014;147(3):473-85.spa
dc.source.bibliographicCitationMcNamara KM, Moore NL, Hickey TE, Sasano H, Tilley WD. Complexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer. 2014;21(4):T161-81.spa
dc.source.bibliographicCitationRobinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, et al. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 2011;30(15):3019-27.spa
dc.source.bibliographicCitationLehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-67.spa
dc.source.bibliographicCitationOrtmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T. Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol. 2002;16(2):113-20.spa
dc.source.bibliographicCitationHurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 2011;43(1):27-33.spa
dc.source.bibliographicCitationBadve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, et al. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Clin Cancer Res. 2007;13(15 Pt 1):4415-21.spa
dc.source.bibliographicCitationHayashi S, Kimura M. Mechanisms of hormonal therapy resistance in breast cancer. Int J Clin Oncol. 2015;20(2):262-7.spa
dc.source.bibliographicCitationHorimoto Y, Arakawa A, Harada-Shoji N, Sonoue H, Yoshida Y, Himuro T, et al. Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases. Br J Cancer. 2015;112(2):345-51.spa
dc.source.bibliographicCitationMehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, et al. FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat. 2012;131(3):881-90.spa
dc.source.bibliographicCitationRoss-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature. 2012;481(7381):389-93.spa
dc.source.bibliographicCitationShou J, Lai Y, Xu J, Huang J. Prognostic value of FOXA1 in breast cancer: A systematic review and meta-analysis. Breast. 2016;27:35-43.spa
dc.source.bibliographicCitationThorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, et al. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol. 2008;61(3):327-32.spa
dc.source.bibliographicCitationWolf I, Bose S, Williamson EA, Miller CW, Karlan BY, Koeffler HP. FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer. 2007;120(5):1013-22.spa
dc.source.bibliographicCitationCiriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 2015;163(2):506-19.spa
dc.source.bibliographicCitationCarroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell. 2005;122(1):33-43.spa
dc.source.bibliographicCitationNi M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011;20(1):119-31.spa
dc.source.bibliographicCitationRobinson JL, Holmes KA, Carroll JS. FOXA1 mutations in hormone-dependent cancers. Front Oncol. 2013;3:20.spa
dc.source.bibliographicCitationGoldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206-23.spa
dc.source.bibliographicCitationCirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M, Zaret KS. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell. 2002;9(2):279-89.spa
dc.source.bibliographicCitationHisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y, et al. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer. Ann Surg Oncol. 2012;19(4):1145-52.spa
dc.source.bibliographicCitationHisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y, et al. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer. Breast Cancer. 2015;22(5):520-8.spa
dc.source.bibliographicCitationLi Z, Nitta H, Hou Y, Banks P. HER2 Intratumoral Heterogeneity Is Associated with Incomplete Response to Anti-HER2 Neoadjuvant Chemotherapy in HER2-Positive Breast Carcinoma. Mod Pathol. 2016;241:55A.spa
dc.source.bibliographicCitationWilliamson EA, Wolf I, O'Kelly J, Bose S, Tanosaki S, Koeffler HP. BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1). Oncogene. 2006;25(9):1391-9.spa
dc.source.bibliographicCitationAdemuyiwa FO, Thorat MA, Jain RK, Nakshatri H, Badve S. Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Mod Pathol. 2010;23(2):270-5.spa
dc.source.bibliographicCitationOh DS, Troester MA, Usary J, Hu Z, He X, Fan C, et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol. 2006;24(11):1656-64.spa
dc.source.bibliographicCitationGao N, Ishii K, Mirosevich J, Kuwajima S, Oppenheimer SR, Roberts RL, et al. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development. 2005;132(15):3431-43.spa
dc.source.bibliographicCitationJia L, Berman BP, Jariwala U, Yan X, Cogan JP, Walters A, et al. Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One. 2008;3(11):e3645.spa
dc.source.bibliographicCitationWang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell. 2007;27(3):380-92.spa
dc.source.bibliographicCitationSahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 2011;30(19):3962-76.spa
dc.source.bibliographicCitationKonecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95(2):142-53.spa
dc.source.bibliographicCitationLal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol. 2005;123(4):541-6spa
dc.source.bibliographicCitationLim TH, Lim AS, Thike AA, Tien SL, Tan PH. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer. Arch Pathol Lab Med. 2016;140(2):140-7.spa
dc.source.bibliographicCitationLong TH, Lawce H, Durum C, Moore SR, Olson SB, Gatter K, et al. The New Equivocal: Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines. Am J Clin Pathol. 2015;144(2):253-62.spa
dc.source.bibliographicCitationMuller KE, Marotti JD, Memoli VA, Wells WA, Tafe LJ. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry. Am J Clin Pathol. 2015;144(2):247-52.spa
dc.source.bibliographicCitationSapino A, Maletta F, Verdun di Cantogno L, Macri L, Botta C, Gugliotta P, et al. Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method. Oncologist. 2014;19(11):1118-26.spa
dc.source.bibliographicCitationShah MV, Wiktor AE, Meyer RG, Tenner KS, Ballman KV, Green SJ, et al. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines. J Clin Oncol. 2016;34(29):3502-10.spa
dc.source.bibliographicCitationGriffin B, Pincus J, Siziopikou KP, LB. B. Reflex Alternate Reference Probe D17S122 in Double (IHC and FISH) Equivocal Invasive Breast Carcinomas May Aid in Establishing True HER2 Status. Modern Pathology. 2017;30(2s):43A.spa
dc.source.bibliographicCitationRagazzi M, Bisagni A, Gasparini E, Kuhn E, Bassano C, Tamagnini I, et al. Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH. Breast. 2017;34:65-72spa
dc.source.bibliographicCitationNatrajan R, Lambros MB, Rodriguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchio C, et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res. 2009;15(8):2711-22.spa
dc.source.bibliographicCitationMurthy SS, Sandhya DG, Ahmed F, Goud KI, Dayal M, Suseela K, et al. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center. Indian J Pathol Microbiol. 2011;54(3):532-8.spa
dc.source.bibliographicCitationFu L, Medico E. FLAME, a novel fuzzy clustering method for the analysis of DNA microarray data. BMC Bioinformatics. 2007;8:3.spa
dc.source.bibliographicCitationMeV 4.8 software. [Available from: http://www.tm4.org.spa
dc.source.bibliographicCitationPinder SE, Provenzano E, Earl H, Ellis IO. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology. 2007;50(4):409-17.spa
dc.source.bibliographicCitationArriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest. 2008;88(5):491-503.spa
dc.source.bibliographicCitationMarchio C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, et al. The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol. 2008;216(4):399-407.spa
dc.source.bibliographicCitationgenomics cfc. [Available from: cbioportal.org.spa
dc.source.bibliographicCitationHanna WM, Ruschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol. 2014;27(1):4-18.spa
dc.source.bibliographicCitationOhlschlegel C, Zahel K, Kradolfer D, Hell M, Jochum W. HER2 genetic heterogeneity in breast carcinoma. J Clin Pathol. 2011;64(12):1112-6.spa
dc.source.bibliographicCitationSwanson PE, Yang H. Is "Polysomy" in Breast Carcinoma the "New Equivocal" in HER2 Testing? Am J Clin Pathol. 2015;144(2):181-4.spa
dc.source.bibliographicCitationOrsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Ursule L, et al. Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes. Cancer Res. 2004;64(18):6453-60.spa
dc.source.bibliographicCitationRondon-Lagos M, Verdun Di Cantogno L, Rangel N, Mele T, Ramirez-Clavijo SR, Scagliotti G, et al. Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells. BMC Cancer. 2014;14:922.spa
dc.source.bibliographicCitationLandmann A, Farrugia D, Diego E, Bonaventura M, Soran A, Johnson R, et al. HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2­positive or HER2­ negative tumors? J Clin Oncol. 2016;34.spa
dc.source.bibliographicCitationPress MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, et al. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. J Clin Oncol. 2016;34(29):3518-28.spa
dc.source.bibliographicCitationBiserni GB, Engstrom MJ, Bofin AM. HER2 gene copy number and breast cancer-specific survival. Histopathology. 2016;69(5):871-9.spa
dc.source.bibliographicCitationSneige N, Hess KR, Multani AS, Gong Y, Ibrahim NK. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. Cancer. 2017;123(7):1115-23.spa
dc.source.bibliographicCitationCriscitiello C, Bagnardi V, Viale G, Disalvatore D, Rotmensz N, Esposito A, et al. HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence. Anticancer Res. 2016;36(7):3537-40.spa
dc.source.bibliographicCitationPerez EA, Ballman KV, Mashadi-Hossein A, Tenner KS, Kachergus JM, Norton N, et al. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial. J Natl Cancer Inst. 2017;109(2).spa
dc.source.bibliographicCitationRhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A. 2009;106(25):10284-9.spa
dc.source.bibliographicCitationAteeq B, Tomlins SA, Chinnaiyan AM. AGTR1 as a therapeutic target in ER-positive and ERBB2-negative breast cancer cases. Cell Cycle. 2009;8(23):3794-5.spa
dc.source.bibliographicCitationde Ronde JJ, Lips EH, Mulder L, Vincent AD, Wesseling J, Nieuwland M, et al. SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Res Treat. 2013;137(1):213-23.spa
dc.source.bibliographicCitationNamazi S, Rostami-Yalmeh J, Sahebi E, Jaberipour M, Razmkhah M, Hosseini A. The role of captopril and losartan in prevention and regression of tamoxifen-induced resistance of breast cancer cell line MCF-7: an in vitro study. Biomed Pharmacother. 2014;68(5):565-71.spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subjectBreast cancerspa
dc.subjectAndrogen Receptorspa
dc.subjectEstrogen Receptorspa
dc.subjectPrognosisspa
dc.subjectMolecular medicinespa
dc.subject.ddcEnfermedadesspa
dc.subject.keywordBreast cancerspa
dc.subject.keywordAndrogen Receptorspa
dc.subject.keywordEstrogen Receptorspa
dc.subject.keywordPrognosisspa
dc.subject.keywordMolecular medicinespa
dc.subject.lembNeoplasias de la mamaspa
dc.subject.lembReceptores androgénicosspa
dc.subject.lembMedicina molecularspa
dc.titleNew molecular approches using AR, FOXA1 and HER2 for outcome classification of estrogen Receptor-Positive (ER+) breast cancers”spa
dc.typedoctoralThesiseng
dc.type.documentAnálisis de casospa
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.type.spaTesis de doctoradospa
local.department.reportEscuela de Medicina y Ciencias de la Saludspa
Archivos
Bloque original
Mostrando1 - 2 de 2
Miniatura
Nombre:
Rangel Nelson 2018-1.pdf
Tamaño:
16.13 MB
Formato:
Adobe Portable Document Format
Descripción:
Documento principal
Descargar
Miniatura
Nombre:
Rangel Nelson 2018-2.pdf
Tamaño:
468.15 KB
Formato:
Adobe Portable Document Format
Descripción:
Anexos
Descargar
Colecciones
Doctorado en Ciencias Biomédicas